Want to join the conversation?
$CVS said Repatha, evolocumab, from $AMGN will be added as only PCSK9 inhibitor for treating low-density lipoprotein cholesterol on the CVS/caremark commercial formularies. The decision comes after thorough evaluation of 2 new PCSK9 inhibitor therapies, which were approved by FDA earlier this year.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?